Acuitas Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 1, 2027The maintenance fee for Lipid Nanoparticle Formulations (US 11,712,481) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Novel Carbonyl Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids (US 11,820,728) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Cationic lipids for use in lipid nanoparticles (US 11,976,019) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Aug 25 US 12,714,670 Novel Carbonyl Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,737,619 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 9,738,593 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 10,106,490 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 10,723,692 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 11,634,379 | Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 10,221,127 | Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 11,168,051 | Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 10,166,298 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 11,040,112 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence | |
| US 11,648,324 | Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
19 pending · 7 abandoned